Effect of Fontan-Associated Morbidities on Survival With Intact Fontan Circulation

被引:71
|
作者
Allen, Kiona Y. [1 ,2 ]
Downing, Tacy E. [2 ]
Glatz, Andrew C. [2 ]
Rogers, Lindsay S. [4 ]
Ravishankar, Chitra [2 ]
Rychik, Jack [2 ]
Fuller, Stephanie [3 ]
Montenegro, Lisa M. [5 ]
Steven, James M. [5 ]
Spray, Thomas L. [3 ]
Nicolson, Susan C. [5 ]
Gaynor, James William [3 ]
Goldberg, David J. [2 ]
机构
[1] Ann & Robert H Lurie Childrens Hosp Chicago, Div Pediat Cardiol, Chicago, IL 60611 USA
[2] Childrens Hosp Philadelphia, Cardiac Ctr, Div Pediat Cardiol, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Cardiac Ctr, Dept Surg, Philadelphia, PA 19104 USA
[4] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Div Pediat Cardiol, Houston, TX 77030 USA
[5] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2017年 / 119卷 / 11期
关键词
TOTAL CAVOPULMONARY CONNECTION; LONG-TERM SURVIVAL; TRICUSPID-ATRESIA; FOLLOW-UP; OPERATION; MULTICENTER; PALLIATION; THROMBOPROPHYLAXIS; COMPLICATIONS; ARRHYTHMIAS;
D O I
10.1016/j.amjcard.2017.03.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although survival after the Fontan operation has improved, little is known about the burden of major medical morbidities associated with the modern total cavopulmonary connection (TCPC). A total of 773 consecutive patients who underwent a first Fontan operation at our institution between 1992 and 2009 were retrospectively reviewed. All subjects underwent TCPC (53% lateral tunnel, 47% extracardiac conduit). Median length of follow-up was 5.3 years (interquartile range 1.4 to 11.2), and 30% had follow-up >10 years. Freedom from a composite medical morbidity outcome (protein -losing enteropathy, plastic bronchitis, serious thromboembolic event, or tachyarrhythmia) was 47% at 20 years (95% confidence interval [CI] 38 to 55). Independent risk factors for morbidity included preFontan atrioventricular valve regurgitation (hazard ratio [HR] 1.7, 95% CI 1.2 to 2.4, p = 0.001), pleural drainage >14 days MR 1.5, 95% CI 1.01 to 2.2, p = 0.04), and longer cross -clamp time (HR 1.2 per 10 minutes, 95% CI 1.06 to 1.3, p = 0.004) at the time of TCPC. Surgical era, Fontan type, and ventricular morphology were not associated with the composite outcome. Presence of Fontan-associated morbidity was associated with a 36 -fold increase in the risk of subsequent Fontan takedown, heart transplantation, or death (95% CI 17 to 76, p <0.001). For patients without any component of the composite outcome, freedom from Fontan failure was 98% at 20 years (95% CI 96 to 99). Medical morbidities after TCPC are common and significantly reduce the longevity of the Fontan circulation. However, for those patients who remain free from the composite morbidity outcome, 20 -year survival with intact Fontan circulation is encouraging. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:1866 / 1871
页数:6
相关论文
共 50 条
  • [1] Fontan-Associated Dyslipidemia
    Lubert, Adam M.
    Alsaied, Tarek
    Palermo, Joseph J.
    Anwar, Nadeem
    Urbina, Elaine M.
    Brown, Nicole M.
    Alexander, Craig
    Almeneisi, Hassan
    Wu, Fred
    Leventhal, Andrew R.
    Aldweib, Nael
    Mendelson, Michael
    Opotowsky, Alexander R.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (07):
  • [2] Fontan-associated liver disease
    Parada Blazquez, M. J.
    Rodriguez Vargas, D.
    Mohigefer Barrera, J.
    Borrero Martin, J. J.
    Vargas Serranoa, B.
    RADIOLOGIA, 2021, 63 (02): : 159 - 169
  • [3] Fontan-Associated Plastic Bronchitis
    Saxena, Pravin
    Maddali, Madan Mohan
    Kaur, Charanjit
    Zacharias, Sunny
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2023, 37 (06) : 1063 - 1064
  • [4] Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics
    Schleiger, Anastasia
    Salzmann, Madeleine
    Kramer, Peter
    Danne, Friederike
    Schubert, Stephan
    Bassir, Christian
    Mueller, Tobias
    Mueller, Hans-Peter
    Berger, Felix
    Ovroutski, Stanislav
    PEDIATRIC CARDIOLOGY, 2020, 41 (04) : 736 - 746
  • [5] Fontan-associated Liver Disease
    Tellez, Luis
    Rodriguez de Santiago, Enrique
    Albillos, Agustin
    REVISTA ESPANOLA DE CARDIOLOGIA, 2018, 71 (03): : 192 - 202
  • [6] Fontan-associated liver disease
    Hilscher, Moira B.
    Wells, Michael L.
    Venkatesh, Sudhakar K.
    Cetta, Frank
    Kamath, Patrick S.
    HEPATOLOGY, 2022, 75 (05) : 1300 - 1321
  • [7] Fontan-Associated Liver Disease
    Gumm, Alexis J.
    Rand, Elizabeth B.
    JOURNAL OF PEDIATRICS, 2025, 277
  • [8] Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics
    Anastasia Schleiger
    Madeleine Salzmann
    Peter Kramer
    Friederike Danne
    Stephan Schubert
    Christian Bassir
    Tobias Müller
    Hans-Peter Müller
    Felix Berger
    Stanislav Ovroutski
    Pediatric Cardiology, 2020, 41 : 736 - 746
  • [9] Imaging of Fontan-Associated Liver Disease
    Brown, Mark J.
    Kolbe, Amy B.
    Hull, Nathan C.
    Hilscher, Moira
    Kamath, Patrick S.
    Yalon, Mariana
    Gu, Chris N.
    Amawi, Ali Dean T.
    Venkatesh, Sudhakar K.
    Wells, Michael L.
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2024, 48 (01) : 1 - 11
  • [10] Improved Survival in Fontan-Associated Protein-Losing Enteropathy
    Veldtman, Gruschen R.
    Webb, Gary D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (01) : 63 - 65